Targeted therapy options for treatment of bone metastases; beyond bisphosphonates

Current Pharmaceutical Design

Volumn 16, Issue 27, 2010, Pages 3015-3027

  Buijs, J T ^a   Kuijpers, C C H J ^a   van der Pluijm, G ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bone metastasis; Breast cancer; Osteoblast; Osteoclasts; Prostate cancer; Tgf beta

Indexed keywords

ACE 011; AMGN 0007; ANTINEOPLASTIC AGENT; AP 11014; AP 12009; ATRASENTAN; BALICATIB; BATIMASTAT; BHQ 880; BISPHOSPHONIC ACID DERIVATIVE; BOSUTINIB; CINACALCET; CTCE 9908; DASATINIB; DENOSUMAB; GLPG 0187; IBANDRONIC ACID; LITHIUM CHLORIDE; MARIMASTAT; N (3 METHOXY 5 METHYL 2 PYRAZINYL) 2 [4 (1,3,4 OXADIAZOL 2 YL)PHENYL] 3 PYRIDINESULFONAMIDE; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; ODANACATIB; PAMIDRONIC ACID; PLERIXAFOR; PRINOMASTAT; RECOMBINANT OSTEOGENIC PROTEIN 1; RELACATIB; SD 208; TANOMASTAT; TC 14012; TN 14003; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIBOTENTAN; ZOLEDRONIC ACID;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE CELL; BONE MARROW CELL; BONE METASTASIS; BONE TUMOR; BONE TURNOVER; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; EXTRACELLULAR MATRIX; HUMAN; NONHUMAN; OSTEOARTHRITIS; OSTEOPOROSIS; PHENOTYPE; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; STROMA CELL; TREATMENT INDICATION; TUMOR MICROENVIRONMENT;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; BONE MARROW; BONE NEOPLASMS; BREAST NEOPLASMS; DIPHOSPHONATES; DRUG DESIGN; FEMALE; HUMANS; MALE; METABOLIC NETWORKS AND PATHWAYS; NEOPLASTIC STEM CELLS; PROSTATIC NEOPLASMS;

EID: 78649809679     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210793563536     Document Type: Article

References (167)

1. Coleman RE, Rubens RD. 3(Amino-1,1-hydroxypropylidene) bisphosphonate (APD) for hypercalcaemia of breast cancer. Br J Cancer 1987; 56: 465-9.
2. Coleman RE. Skeletal complications of malignancy. Cancer 1997; 80: 1588-94.
3. Eaton CL, Colombel M, van der Pluijm G, et al. Evaluation of the frequency of putative prostate cancer stem cells in primary and metastatic prostate cancer. Prostate 2010; 70: 875-82.
4. Elte JW, Bijvoet OL, Cleton FJ, van Oosterom AT, Sleeboom HP. Osteolytic bone metastases in breast carcinoma pathogenesis, morbidity and bisphosphonate treatment. Eur J Cancer Clin Oncol 1986; 22: 493-500.
5. Powles T, Paterson S, Kanis JA, et al. Randomized, placebocontrolled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002; 20: 3219-24.
6. van Holten-Verzantvoort AT, Bijvoet OL, Cleton FJ, et al. Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment. Lancet 1987; 2: 983-5.
7. Rubens RD. In: Rubens RD, Fogelman I, Eds. Bone metastases - diagnosis and treatment. Springer-Verlag, London 1991; pp. 1-10.
8. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004; 350: 1655-64.
9. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889; 1: 571-3.
10. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003; 3: 453-8.
11. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001; 411: 375-9.
12. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66.
13. Alberts B, Bray D, Lewis J, Raff M, Roberts K, Watson JD. Molecular biology of the cell. Garland Publishing, Inc., New York & London 1994; 1255-91.
14. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelialmesenchymal transitions in development and disease. Cell 2009 139(5): 871-90. [Review].
15. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Inv 2009; 119(6); 1420-8.
16. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2: 584-93.
17. Yin T, Li L. The stem cell niches in bone. J Clin Invest 2006; 116: 1195-201.
18. Corboz VA, Cecchini MG, Felix R, Fleisch H, van der Pluijm G, Löwik CW. Effect of macrophage colony-stimulating factor on in vitro osteoclast generation and bone resorption. Endocrinology 1992; 130(1): 437-42.
19. Teitelbaum SL. Osteoclasts: what do they do and how do they do it? Am J Pathol 2007; 170: 427-35.
20. Schlesinger PH, Blair HC, Teitelbaum SL, Edwards JC. Characterization of the osteoclast ruffled border chloride channel and its role in bone resorption. J Biol Chem 1997; 272: 18636-43.
21. Blair HC, Kahn AJ, Crouch EC, Jeffrey JJ, Teitelbaum SL. Isolated osteoclasts resorb the organic and inorganic components of bone. J Cell Biol 1986; 102: 1164-72.
22. Buijs JT, Que I, Lowik CW, Papapoulos SE, van der PG. Inhibition of bone resorption and growth of breast cancer in the bone microenvironment. Bone 2009; 44: 380-6.
23. Cicek M, Oursler MJ. Breast cancer bone metastasis and current small therapeutics. Cancer Metastasis Rev 2006; 25: 635-44.
24. Guise TA, Yin JJ, Thomas RJ, Dallas M, Cui Y, Gillespie MT. Parathyroid hormone-related protein (PTHrP)-(1-139) isoform is efficiently secreted in vitro and enhances breast cancer metastasis to bone in vivo. Bone 2002; 30: 670-6.
25. Dunn LK, Mohammad KS, Fournier PG, et al. Hypoxia and TGFbeta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PLoS One 2009; 4: e6896.
26. Le GC, Bellahcene A, Bonnelye E, et al. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Cancer Res 2007; 67: 9894-902.
27. Thomas RJ, Guise TA, Yin JJ, et al. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 1999; 140: 4451-8.
28. Yin JJ, Selander K, Chirgwin JM, et al. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 1999; 103: 197-206.
29. Henderson M, Danks J, Moseley J, et al. Parathyroid hormonerelated protein production by breast cancers, improved survival, and reduced bone metastases. J Natl Cancer Inst 2001; 93: 234-7.
30. Lu X, Wang Q, Hu G, et al. ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. Genes Dev 2009; 23: 1882-94.
31. Korpal M, Yan J, Lu X, Xu S, Lerit DA, Kang Y. Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat Med 2009; 15: 960-6.
32. Body JJ, Greipp P, Coleman RE, et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 2003; 97: 887-92.
33. Virk MS, Lieberman JR. Tumor metastasis to bone. Arthritis Res Ther 2007; 9 Suppl 1: S5.
34. Buijs JT, van der PG. Osteotropic cancers: from primary tumor to bone. Cancer Lett 2009; 273: 177-93.
35. Guise TA, Mundy GR. Cancer and bone. Endocr Rev 1998; 19: 18-54.
36. Schwaninger R, Rentsch CA, Wetterwald A, et al. Lack of noggin expression by cancer cells is a determinant of the osteoblast response in bone metastases. Am J Pathol 2007; 170: 160-75.
37. Clark JC, Dass CR, Choong PF. Current and future treatments of bone metastases. Expert Opin Emerg Drugs 2008; 13: 609-27.
38. Goltzman D. Mechanisms of the development of osteoblastic metastases. Cancer 1997; 80: 1581-7.
39. Yonou H, Horiguchi Y, Ohno Y, et al. Prostate-specific antigen stimulates osteoprotegerin production and inhibits receptor activator of nuclear factor-kappaB ligand expression by human osteoblasts. Prostate 2007; 67: 840-8.
40. Hattner R, Epker BN, Frost HM. Suggested sequential mode of control of changes in cell behaviour in adult bone remodelling. Nature 1965; 206: 489-90.
41. Mundy GR. In: Favus MJ Eds, Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Lippincott Williams&Wilkins, Philadelphia 1999; 30-8.
42. Guise TA, Yin JJ, Taylor SD, et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 1996; 98: 1544-9.
43. van der Pluijm G, Que I, Sijmons B, et al. Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivo. Cancer Res 2005; 1; 65(17): 7682-90.
44. Garlanda C, Dejana E. Heterogeneity of endothelial cells. Specific markers. Arterioscler Thromb Vasc Biol 1997; 17: 1193-202.
45. McCarthy SA, Kuzu I, Gatter KC, Bicknell R. Heterogeneity of the endothelial cell and its role in organ preference of tumour metastasis. Trends Pharmacol Sci 1991; 12: 462-7.
46. Cher ML. Mechanisms governing bone metastasis in prostate cancer. Curr Opin Urol 2001; 11: 483-8.
47. Fernandis AZ, Prasad A, Band H, Klosel R, Ganju RK. Regulation of CXCR4-mediated chemotaxis and chemoinvasion of breast cancer cells. Oncogene 2004; 23: 157-67.
48. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50-6.
49. Jones DH, Nakashima T, Sanchez OH, et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 2006; 440: 692-6.
50. Hall CL, Dai J, van Golen KL, Keller ET, Long MW. Type I collagen receptor (alpha 2 beta 1) signaling promotes the growth of human prostate cancer cells within the bone. Cancer Res 2006; 66: 8648-54.
51. Sloan EK, Pouliot N, Stanley KL, et al. Tumor-specific expression of alphavbeta3 integrin promotes spontaneous metastasis of breast cancer to bone. Breast Cancer Res 2006; 8: R20.
52. van der Pluijm G, Sijmons B, Vloedgraven H, et al. Urokinasereceptor/ integrin complexes are functionally involved in adhesion and progression of human breast cancer in vivo. Am J Pathol 2001: 159(3); 971-82.
53. van der Pluijm G, Vloedgraven HJ, Ivanov B, et al. Bone sialoprotein peptides are potent inhibitors of breast cancer cell adhesion to bone. Cancer Res 1996: 15; 56(8); 1948-55.
54. Durr HR, Muller PE, Lenz T, Baur A, Jansson V, Refior HJ. Surgical treatment of bone metastases in patients with breast cancer. Clin Orthop Relat Res 2002; 191-6.
55. Kawatani M, Osada H. Osteoclast-targeting small molecules for the treatment of neoplastic bone metastases. Cancer Sci 2009; 100: 1999-2005.
56. Winter MC, Coleman RE. Bisphosphonates in breast cancer: teaching an old dog new tricks. Curr Opin Oncol 2009; 21: 499-506.
57. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998 Mar 31; 95(7): 3597-602.
58. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93(2): 165-76.
59. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999; 20(3): 345-57.
60. Wong BR, Josien R, Choi Y. TRANCE is a TNF family member that regulates dendritic cell and osteoclast function. J Leukoc Biol 1999; 65(6): 715-24.
61. Burgess TL, Qian Y, Kaufman S, et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 1999; 145(3): 527-38.
62. Hsu H, Lacey DL, Dunstan CR, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 1999; 96(7): 3540-5.
63. Takahashi N, Udagawa N, Suda T. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochem Biophys Res Commun 1999; 256(3): 449-55.
64. Fuller K, Wong B, Fox S, Choi Y, Chambers TJ. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med 1998; 188(5): 997-1001.
65. Neville-Webbe HL, Cross NA, Eaton CL, et al. Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. Breast Cancer Res Treat 2004; 86: 269-79.
66. Canon JR, Roudier M, Bryant R, et al. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis 2008; 25: 119-29.
67. Zhang J, Dai J, Qi Y, et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001; 107: 1235-44.
68. Whang PG, Schwarz EM, Gamradt SC, Dougall WC, Lieberman JR. The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone. J Orthop Res 2005; 23: 1475-83.
69. Morony S, Warmington K, Adamu S, et al. The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy. Endocrinology 2005; 146: 3235-43.
70. Chanda D, Isayeva T, Kumar S, et al. Systemic osteoprotegerin gene therapy restores tumor-induced bone loss in a therapeutic model of breast cancer bone metastasis. Mol Ther 2008; 16: 871-8.
71. Nicolin V, Narducci P. Soluble TRAIL could enhance bone destruction acting on Rank-ligand in estrogen-independent human breast cancer cell line MDA-MB-231. Acta Histochem 2010; 112: 189-92.
72. Abrahamsen B, Teng AY. Technology evaluation: denosumab, Amgen. Curr Opin Mol Ther 2005; 7: 604-10.
73. Kostenuik PJ, Nguyen HQ, McCabe J, et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res 2009; 24: 182-95.
74. Bartsch R, Steger GG. Role of denosumab in breast cancer. Expert Opin Biol Ther 2009; 9: 1225-33.
75. Lipton A, Steger GG, Figueroa J, et al. Randomized activecontrolled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 2007; 25: 4431-7.
76. Fizazi K, Lipton A, Mariette X, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009; 27: 1564-71.
77. Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004; 19: 1059-66.
78. Stopeck A, Body JJ, Fujiwara Y, et al. Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study. Eur J Cancer Suppl 2009; 7: 2-3.
79. Smith MR, Egerdie B, Hernandez TN, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009; 361: 745-55.
80. Brubaker KD, Vessella RL, True LD, Thomas R, Corey E. Cathepsin K mRNA and protein expression in prostate cancer progression. J Bone Miner Res 2003; 18: 222-30.
81. Grabowskal U, Chambers TJ, Shiroo M. Recent developments in cathepsin K inhibitor design. Curr Opin Drug Discov Devel 2005; 8: 619-30.
82. Grosios K, Altmann E, Gasser JA, Stumm M, Zimmermann J. Efficacy of the bisphosphonate Zometa and the selective cathepsin K inhibitor AFG495 administered alone or in combination in a murine xenograft model of breast cancer cell induced osteolysis. Proc Am Assoc Cancer Res 2005; 46.
83. Peroni A, Zini A, Braga V, Colato C, Adami S, Girolomoni G. Drug-induced morphea: report of a case induced by balicatib and review of the literature. J Am Acad Dermatol 2008; 59: 125-9.
84. Gauthier JY, Chauret N, Cromlish W, et al. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett 2008; 18: 923-8.
85. Deal C. Potential new drug targets for osteoporosis. Nat Clin Pract Rheumatol 2009; 5: 20-7.
86. Oft M, Peli J, Rudaz C, Schwarz H, Beug H, Reichmann E. TGFbeta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev 1996; 10: 2462-77.
87. Roberts AB, Wakefield LM. The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci USA 2003; 100: 8621-3.
88. Ellenrieder V, Hendler SF, Boeck W, et al. Transforming growth factor beta1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. Cancer Res 2001; 61: 4222-8.
89. Peinado H, Quintanilla M, Cano A. Transforming growth factor beta-1 induces snail transcription factor in epithelial cell lines: mechanisms for epithelial mesenchymal transitions. J Biol Chem 2003; 278: 21113-23
90. Piek E, Moustakas A, Kurisaki A, Heldin CH, Ten Dijke P. TGF- (beta) type I receptor/ALK-5 and Smad proteins mediate epithelial to mesenchymal transdifferentiation in NMuMG breast epithelial cells. J Cell Sci 1999; 112: 4557-68.
91. Yang YA, Dukhanina O, Tang B, et al. Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. J Clin Invest 2002; 109: 1607-15.
92. Deckers M, van Dinther M, Buijs J, et al. The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res 2006; 66: 2202-9.
93. Kang Y, He W, Tulley S, et al. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci USA 2005; 102: 13909-14.
94. Schlingensiepen KH, Fischer-Blass B, Schmaus S, Ludwig S. Antisense therapeutics for tumor treatment: the TGF-beta2 inhibitor AP 12009 in clinical development against malignant tumors. Recent Results Cancer Res 2008; 177: 137-50.: 137-50.
95. Mohammad KS, Chen CG, Balooch G, et al. Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone. PLoS One 2009; 4: e5275.
96. Buijs JT, Henriquez NV, van Overveld PG, van der HG, Ten Dijke P, van der PG. TGF-beta and BMP7 interactions in tumour progression and bone metastasis. Clin Exp Metastasis 2007; 24: 609-17.
97. Buijs JT, Rentsch CA, van der Horst G, et al. BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent Inhibitor of prostate cancer bone metastasis in vivo. Am J Pathol 2007; 171: 1047-57.
98. Buijs JT, Henriquez NV, van Overveld PG, et al. Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer. Cancer Res 2007; 67: 8742-51.
99. Leto G, Incorvaia L, Badalamenti G, et al. Activin A circulating levels in patients with bone metastasis from breast or prostate cancer. Clin Exp Metastasis 2006; 23: 117-22.
100. Mulivor AW, Barbosa D, Kumar R, Pearsall AE, Underwood KW, Ucran J et al. RAP-011, a soluble activin type IIA murine IgG-Fc fusion protein, is a novel bone anabolic agent that prevents bone loss and skeletal metastases in a mouse model of metastatic breast cancer. Bone 2010; 44: S221-2.
101. Pearsall RS, Canalis E, Cornwall-Brady M, et al. A soluble activin type IIA receptor induces bone formation and improves skeletal integrity. Proc Natl Acad Sci USA 2008; 105: 7082-7.
102. Edwards CM, Edwards JR, Lwin ST, et al. Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood 2008; 111: 2833-42.
103. Fulciniti M, Tassone P, Hideshima T, et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 2009; 114: 371-9.
104. Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy JD, Jr. Antibody-based inhibition of DKK1 suppresses tumorinduced bone resorption and multiple myeloma growth in vivo. Blood 2007; 109: 2106-11.
105. Li X, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 2009; 24: 578-88.
106. Mihai R, Stevens J, McKinney C, Ibrahim NB. Expression of the calcium receptor in human breast cancer--a potential new marker predicting the risk of bone metastases. Eur J Surg Oncol 2006; 32: 511-5.
107. Casimiro S, Guise TA, Chirgwin J. The critical role of the bone microenvironment in cancer metastases. Mol Cell Endocrinol 2009; 310: 71-81.
108. Saidak Z, Boudot C, Abdoune R, et al. Extracellular calcium promotes the migration of breast cancer cells through the activation of the calcium sensing receptor. Exp Cell Res 2009; 315: 2072-80.
109. Sanders JL, Chattopadhyay N, Kifor O, Yamaguchi T, Butters RR, Brown EM. Extracellular calcium-sensing receptor expression and its potential role in regulating parathyroid hormone-related peptide secretion in human breast cancer cell lines. Endocrinology 2000; 141: 4357-64.
110. Torres PU. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease. J Ren Nutr 2006; 16: 253-8.
111. Burger JA, Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 2009; 23: 43-52.
112. Richert MM, Vaidya KS, Mills CN, et al. Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone. Oncol Rep 2009; 21: 761-7.
113. Huang EH, Singh B, Cristofanilli M, et al. A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J Surg Res 2009; 155: 231-6.
114. Azab AK, Runnels JM, Pitsillides C, et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 2009; 113: 4341-51.
115. Tamamura H, Hori A, Kanzaki N, et al. T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer. FEBS Lett 2003; 550: 79-83.
116. Carducci MA, Jimeno A. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. Clin Cancer Res 2006; 12: 6296s-300s.
117. Alam AS, Gallagher A, Shankar V, et al. Endothelin inhibits osteoclastic bone resorption by a direct effect on cell motility: implications for the vascular control of bone resorption. Endocrinology 1992; 130: 3617-24.
118. Russo A, Bronte G, Rizzo S, et al. Anti-endothelin drugs in solid tumors. Expert Opin Emerg Drugs 2010; 15: 27-40.
119. Guise TA, Yin JJ, Mohammad KS. Role of endothelin-1 in osteoblastic bone metastases. Cancer 2003; 97: 779-84.
120. James ND, Caty A, Borre M, et al. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebocontrolled, randomised, phase 2 trial. Eur Urol 2009; 55: 1112-23.
121. Weterman MA, Ajubi N, van Dinter IM, et al. nmb, a novel gene, is expressed in low-metastatic human melanoma cell lines and xenografts. Int J Cancer 1995; 60: 73-81.
122. Rich JN, Shi Q, Hjelmeland M, et al. Bone-related genes expressed in advanced malignancies induce invasion and metastasis in a genetically defined human cancer model. J Biol Chem 2003; 278: 15951-7.
123. Rose AA, Siegel PM. Emerging therapeutic targets in breast cancer bone metastasis. Future Oncol 2010; 6: 55-74.
124. Rose AA, Pepin F, Russo C, Abou Khalil JE, Hallett M, Siegel PM. Osteoactivin promotes breast cancer metastasis to bone. Mol Cancer Res 2007; 5: 1001-14.
125. Ogawa T, Nikawa T, Furochi H, et al. Osteoactivin upregulates expression of MMP-3 and MMP-9 in fibroblasts infiltrated into denervated skeletal muscle in mice. Am J Physiol Cell Physiol 2005; 289: C697-707.
126. Tse KF, Jeffers M, Pollack VA, et al. CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma. Clin Cancer Res 2006; 12: 1373-82.
127. Hennipman A, van Oirschot BA, Smits J, Rijksen G, Staal GE. Tyrosine kinase activity in breast cancer, benign breast disease, and normal breast tissue. Cancer Res 1989; 49: 516-21.
128. Myoui A, Nishimura R, Williams PJ, et al. C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis. Cancer Res 2003; 63: 5028-33.
129. de Vries TJ, Mullender MG, van Duin MA, et al. The Src inhibitor AZD0530 reversibly inhibits the formation and activity of human osteoclasts. Mol Cancer Res 2009; 7: 476-88.
130. Marzia M, Sims NA, Voit S, et al. Decreased c-Src expression enhances osteoblast differentiation and bone formation. J Cell Biol 2000; 151: 311-20.
131. Chinni SR, Yamamoto H, Dong Z, Sabbota A, Bonfil RD, Cher ML. CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone. Mol Cancer Res 2008; 6: 446-57.
132. Shor AC, Keschman EA, Lee FY, et al. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res 2007; 67: 2800-8.
133. Araujo JC, Poblenz A, Corn P, et al. Dasatinib inhibits both osteoclast activation and prostate cancer PC-3 cell-induced osteoclast formation. Cancer Biol Ther 2009; 8: 2153-9.
134. Zhang XH, Wang Q, Gerald W, et al. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 2009; 16: 67-78.
135. Mendiratta P, Mostaghel E, Guinney J, et al. Genomic strategy for targeting therapy in castration-resistant prostate cancer. J Clin Oncol 2009; 27: 2022-9.
136. Yu E, Massard C, Gross M, et al. A phase II study of once-daily dasatinib for patients with castration-resistant prostate cancer. J Clin Oncol Suppl 2009; 27: 15s.
137. Lara PN, Jr., Longmate J, Evans CP, et al. A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anticancer Drugs 2009; 20: 179-84.
138. Jallal H, Valentino ML, Chen G, Boschelli F, Ali S, Rabbani SA. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. Cancer Res 2007; 67: 1580-8.
139. Campone M, Bondarenko I, Broggi G. Preliminary results of a phase 2 study of bosutinib (SKI-606), a dual Scr/Abl kinase inhibitor, in patients with advanced breast cancer. Proc SABCS 2007; Abstract 6062.
140. Saad F, Lipton A. SRC kinase inhibition: Targeting bone metastases and tumor growth in prostate and breast cancer. Cancer Treat Rev 2009; 36: 177-84.
141. Ray JM, Stetler-Stevenson WG. The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis. Eur Respir J 1994; 7: 2062-72.
142. Stetler-Stevenson WG, Hewitt R, Corcoran M. Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. Semin Cancer Biol 1996; 7: 147-54.
143. Wilson TJ, Singh RK. Proteases as modulators of tumor-stromal interaction: primary tumors to bone metastases. Biochim Biophys Acta 2008; 1785: 85-95.
144. Gohji K, Fujimoto N, Hara I, et al. Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension. Int J Cancer 1998; 79: 96-101.
145. Moses MA, Wiederschain D, Loughlin KR, Zurakowski D, Lamb CC, Freeman MR. Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res 1998; 58: 1395-9.
146. Aparicio T, Kermorgant S, Dessirier V, Lewin MJ, Lehy T. Matrix metalloproteinase inhibition prevents colon cancer peritoneal carcinomatosis development and prolongs survival in rats. Carcinogenesis 1999; 20: 1445-51.
147. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002; 295: 2387-92.
148. Guo W, Giancotti FG. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 2004; 5: 816-26.
149. van der Pluijm G, Vloedgraven H, Papapoulos SE, et al. Attachment characteristics and involvement of integrins in adhesion of breast cancer cell lines to extracellular bone matrix components. Lab Invest 1997; 77: 665-75.
150. Harms JF, Welch DR, Samant RS, et al. A small molecule antagonist of the alpha(v)beta3 integrin suppresses MDA-MB-435 skeletal metastasis. Clin Exp Metastasis 2004; 21: 119-28.
151. McCabe NP, De S, Vasanji A, Brainard J, Byzova TV. Prostate cancer specific integrin alphavbeta3 modulates bone metastatic growth and tissue remodeling. Oncogene 2007; 26: 6238-43.
152. Sun YX, Fang M, Wang J, Cooper CR, Pienta KJ, Taichman RS. Expression and activation of alpha(v)beta(3) integrins by SDF-1/CXC12 increases the aggressiveness of prostate cancer cells. Prostate 2007; 67: 61-73.
153. Zhao Y, Bachelier R, Treilleux I, et al. Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases. Cancer Res 2007; 67: 5821-30.
154. Pecheur I, Peyruchaud O, Serre CM, et al. Integrin alpha(v)beta3 expression confers on tumor cells a greater propensity to metastasize to bone. FASEB J 2002; 16: 1266-8.
155. Karadag A, Ogbureke KU, Fedarko NS, Fisher LW. Bone sialoprotein, matrix metalloproteinase 2, and alpha(v)beta3 integrin in osteotropic cancer cell invasion. J Natl Cancer Inst 2004; 96: 956-65.
156. Engleman VW, Nickols GA, Ross FP, et al. A peptidomimetic antagonist of the alpha(v)beta3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. J Clin Invest 1997; 99: 2284-92.
157. Nemeth JA, Harb JF, Barroso U, Jr., He Z, Grignon DJ, Cher ML. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone. Cancer Res 1999; 59: 1987-93.
158. van der Horst G et al. GLPG0187, a small molecule integrin antagonist, is a potent inhibitor of prostate cancer bone metastasis. Manuscript in preparation.
159. Lorenzon G, Gheyle L, Vets E, et al. GLPG0187, a small molecule integrin antagonist, shows good safety and decrease in CTX levels in single ascending dose study. Poster 1568 Am Association Cancer Res 2010.
160. Winquist RJ, Boucher DM, Wood M, Furey BF. Targeting cancer stem cells for more effective therapies: Taking out cancer's locomotive engine. Biochem Pharmacol 2009; 78: 326-34.
161. Albini A, Sporn MB. The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer 2007; 7: 139-47.
162. Hengst V, Oussoren C, Kissel T, Storm G. Bone targeting potential of bisphosphonate-targeted liposomes. Preparation, characterization and hydroxyapatite binding in vitro. Int J Pharm 2007; 331: 224-7.
163. van den Hoogen C, van der Horst G, Cheung YH, et al. High Aldehyde Dehydrogenase Activity Identifies Tumor-initiating and Metastasis-initiating Cells in Human Prostate Cancer. Cancer Res 2010; 70: 5163-73.
164. Piccirillo SG, Reynolds BA, Zanetti N, et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumourinitiating cells. Nature 2006; 444: 761-5.
165. Buckle CH, Neville-Webbe HL, Croucher PI, Lawson MA. Targeting RANK/RANKL in the Treatment of Solid Tumours and Myeloma. Curr Pharm Des 2010; 16(11): 1272-83.
166. Holen I, Coleman RE. Bisphosphonates as Treatment of Bone Metastases. Curr Pharm Des 2010; 15(11): 1262-71.
167. Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003; 9(32): 2643-58.